All the news Showing 10 of 33 articles from: CirrhosisGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US Liz Highleyman / 05 March 2015 The burden of hepatitis C virus (HCV) infection is high in the US, with a substantial number of individuals born between 1945 and 1965 having advanced fibrosis or cirrhosis and therefore being at ... Many hepatitis C patients with cirrhosis or advanced fibrosis face liver failure and liver cancer Liz Highleyman / 07 January 2015 Nearly one-third of chronic hepatitis C patients with liver cirrhosis and 12% with advanced fibrosis progressed to decompensation within five years, and 23% and 11%, respectively, died, according to a study presented ... Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection Liz Highleyman / 14 November 2014 An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates for treatment-naive and treatment-experienced people with genotype 1 hepatitis C ... Low uptake of HCV treatment in England will lead to substantial disease burden by 2035 Michael Carter / 24 June 2014 Only 3% of people with chronic hepatitis C virus (HCV) are treated for their infection each year in England, according to research published in the Journal of Hepatology. The current uptake of ... Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease Liz Highleyman / 17 April 2014 Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and people who experience severe hepatitis ... Successful hepatitis C treatment reduces risk of liver cancer and death, but most remain untreated Liz Highleyman / 19 November 2013 Hepatitis C treatment that leads to viral cure significantly reduces the likelihood of liver disease progression and liver-related mortality, but most people with hepatitis C remain untreated, according to a presentation at The Liver ... BMS interferon-free combination cures over 90% of genotype 1 hepatitis C in 12 weeks Keith Alcorn / 06 November 2013 A combination of three direct-acting antivirals developed by Bristol-Myers Squibb cured chronic hepatitis C infection in over 90% of previously untreated patients in a mid-stage study, Gregory Everson of the University of Colorado ... In ELECTRON trial, 100% of hard-to-treat patients cured with sofosbuvir/ledipasvir plus ribavirin or GS-9669 Liz Highleyman / 05 November 2013 Interferon-free regimens of sofosbuvir and ledipasvir plus either ribavirin or GS-9669 taken for 12 weeks produced sustained response in 100% of treatment-experienced people with genotype 1 chronic hepatitis C virus (HCV) with advanced ... People with HIV/HCV co-infection and advanced liver fibrosis can rapidly develop decompensated liver disease Michael Carter / 10 September 2013 People living with HIV who have hepatitis C virus (HCV) co-infection and advanced liver fibrosis can rapidly develop decompensated liver disease even though they do not have cirrhosis of the liver, ... Decompensated cirrhosis increases risk of liver cancer for people with HIV and viral hepatitis co-infection Michael Carter / 10 September 2013 There is a relatively low incidence of hepatocellular carcinoma (HCC) among people living with HIV who have liver cirrhosis, results of a prospective Spanish study published in the online edition of the ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive